Nektar Therapeutics (NKTR) Shares Outstanding (Weighted Average) (2010 - 2026)

Nektar Therapeutics' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $24.7 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 75.89% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (up 75.89% YoY), while the FY2025 annual figure was $16.9 million, up 23.05% from the prior year.
• Shares Outstanding (Weighted Average) was $24.7 million for Q1 2026 at Nektar Therapeutics, up from $16.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $194.7 million in Q1 2024 to a low of $13.6 million in Q3 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $107.4 million across 5 years, with a median of $185.8 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Weighted Average) sank 92.82% in 2024, then jumped 75.89% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $187.1 million in 2022, then rose by 1.53% to $190.0 million in 2023, then plunged by 92.78% to $13.7 million in 2024, then increased by 23.05% to $16.9 million in 2025, then soared by 46.62% to $24.7 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $24.7 million (Q1 2026), $16.9 million (Q4 2025), and $15.7 million (Q3 2025), per Business Quant data.